Optimizing Glucose Control with Rybelsus

Prioritizing Therapy Based on Comorbidities

The American Diabetes Association recommends adding an SGLT2 inhibitor to Rybelsus immediately for patients with atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, regardless of current A1C level, as SGLT2 inhibitors reduce cardiovascular death and heart failure hospitalizations independent of glucose-lowering effects 1, 3, 4
For patients with heart failure, SGLT2 inhibitors are specifically recommended to prevent hospitalizations, according to the American Heart Association 4
For patients with chronic kidney disease, SGLT2 inhibitors reduce progression of kidney disease, as stated by the National Kidney Foundation 4

The American Association of Clinical Endocrinologists recommends adding basal insulin or switching to injectable semaglutide/tirzepatide for patients with an A1C gap of 1.5% or more above goal, as these therapies provide high-potency glucose lowering 1, 2
Injectable semaglutide and tirzepatide provide the greatest A1C reductions among all glucose-lowering agents, with lower hypoglycemia risk and weight loss benefits, according to the Endocrine Society 2, 3

The American Diabetes Association recommends verifying Rybelsus dosing is optimized and confirming adherence before adding medications, as poor absorption from incorrect administration is a common cause of apparent treatment failure 5
When adding insulin or sulfonylureas to Rybelsus, the European Association for the Study of Diabetes recommends reducing the dose of insulin or sulfonylurea by 20-30% at initiation to prevent hypoglycemia 6
The American Diabetes Association advises against discontinuing Rybelsus when adding therapy, as the combination provides additive glucose-lowering effects and Rybelsus offers cardiovascular benefits beyond glycemic control 1, 3